Darbie Maccubbin
About
Darbie Maccubbin is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Immunology.
According to data from OpenAlex, Darbie Maccubbin has authored 62 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 28 papers in Endocrinology, Diabetes and Metabolism and 14 papers in Immunology. Recurrent topics in Darbie Maccubbin's work include Lipoproteins and Cardiovascular Health (31 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (24 papers) and Immunotherapy and Immune Responses (9 papers). Darbie Maccubbin is often cited by papers focused on Lipoproteins and Cardiovascular Health (31 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (24 papers) and Immunotherapy and Immune Responses (9 papers). Darbie Maccubbin collaborates with scholars based in United States, Spain and Norway. Darbie Maccubbin's co-authors include Enrico Mihich, M. Jane Ehrke, Christine McCrary Sisk, Yale Mitchel, Arvind Shah, Harold Bays, Louis W. Schierman, Srđan Verstovšek, John F. Paolini and Enrico P. Veltri and has published in prestigious journals such as The Journal of Immunology, The American Journal of Cardiology and International Journal of Cancer.
In The Last Decade
Darbie Maccubbin
62 papers receiving 1.4k citations
Peers
Darbie Maccubbin
A.F.H. Stalenhoef Netherlands
Fabio Pellegatta Italy
W Jaroß Germany
Seiko Otokozawa United States
Choong Hwan Kwak South Korea
Bin Zhao China
Ana Cenarro Spain
Constantinos C. Tellis Greece
Joan-Carles Vallvé Spain
Melba Hernandez United States
Citations per year, relative to Darbie Maccubbin Darbie Maccubbin (= 1×)
peers
A.F.H. Stalenhoef
Countries citing papers authored by Darbie Maccubbin
Since
Specialization
Citations
This map shows the geographic impact of Darbie Maccubbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darbie Maccubbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darbie Maccubbin more than expected).
Fields of papers citing papers by Darbie Maccubbin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Darbie Maccubbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darbie Maccubbin. The network helps show where Darbie Maccubbin may publish in the future.
Co-authorship network of co-authors of Darbie Maccubbin
This figure shows the co-authorship network connecting the top 25 collaborators of Darbie Maccubbin. A scholar is included among the top collaborators of Darbie Maccubbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darbie Maccubbin. Darbie Maccubbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Brinton, Eliot A., Joseph Triscari, Philippe Brudi, et al.. (2016). Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in Health and Disease. 15(1). 116–116.
2.
Maccubbin, Darbie, et al.. (2013). Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. International Journal of Clinical Practice. 67(4). 297–302.
3.
Maccubbin, Darbie, Diane Tipping, Olga Kuznetsova, William A. Hanlon, & Andrew G. Bostom. (2010). Hypophosphatemic Effect of Niacin in Patients without Renal Failure. Clinical Journal of the American Society of Nephrology. 5(4). 582–589.
4.
McKenney, James M., Harold Bays, Michael J. Koren, et al.. (2010). Safety of extended-release niacin/laropiprant in patients with dyslipidemia. Journal of clinical lipidology. 4(2). 105–112.e1.
5.
Kush, Debra, Hyo-Soo Kim, Ji Liu, et al.. (2009). Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. Journal of clinical lipidology. 3(3). 179–186.
6.
Maccubbin, Darbie, Michael J. Koren, Michael Davidson, et al.. (2009). Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease. The American Journal of Cardiology. 104(1). 74–81.
7.
Feldman, Theodore, Leiv Ose, Arvind Shah, et al.. (2007). Efficacy and Safety of Ezetimibe/Simvastatin Versus Simvastatin Monotherapy in Hypercholesterolemic Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 5(1). 13–21.
8.
Pearson, Thomas A., Christie M. Ballantyne, Christine McCrary Sisk, et al.. (2007). Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels. The American Journal of Cardiology. 99(12). 1706–1713.e1.
9.
Ose, Leiv, Arvind Shah, Michael J. Davies, et al.. (2006). Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Current Medical Research and Opinion. 22(5). 823–835.
10.
Feldman, Theodore, Michael H. Davidson, Arvind Shah, et al.. (2006). Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials. Clinical Therapeutics. 28(6). 849–859.
11.
Davidson, Michael H., et al.. (2005). Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin). The American Journal of Cardiology. 97(2). 223–228.
12.
Lewin, Andrew, Mark Kipnes, Luigi Meneghini, et al.. (2004). Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 26(3). 379–389.
13.
Simons, Leon A., Melvin J. Tonkon, L. Masana, et al.. (2004). Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Current Medical Research and Opinion. 20(9). 1437–1445.
14.
Isaacsohn, Jonathan L., Donald B. Hunninghake, Helmut G. Schrott, et al.. (2003). Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia. Clinical Cardiology. 26(1). 18–24.
15.
Bays, Harold, Evan A. Stein, Arvind Shah, et al.. (2002). Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. The American Journal of Cardiology. 90(9). 942–946.
16.
Ehrke, M. Jane, Srđan Verstovšek, Darbie Maccubbin, et al.. (2000). Protective specific immunity induced by doxorubicin plus TNF-α combination treatment of EL4 lymphoma-bearing C57BL/6 mice. International Journal of Cancer. 87(1). 101–109.
17.
Ehrke, M. Jane, Srđan Verstovšek, Peter Ujházy, et al.. (1998). Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunology Immunotherapy. 45(6). 287–298.
18.
Ehrke, M. Jane, et al.. (1996). Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunology Immunotherapy. 42(4). 221–230.
19.
Ehrke, M. Jane, et al.. (1995). Cyclophosphamide plus tumor necrosis factor‐α chemoimmunotherapy cured mice: Life‐long immunity and rejection of re‐implanted primary lymphoma. International Journal of Cancer. 63(3). 463–471.
20.
Verstovšek, Srđan, et al.. (1995). Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor α combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunology Immunotherapy. 40(6). 347–357.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A.F.H. Stalenhoef Breakdown of academic impact, for papers by Fabio Pellegatta Breakdown of academic impact, for papers by W Jaroß Breakdown of academic impact, for papers by Seiko Otokozawa Breakdown of academic impact, for papers by Choong Hwan Kwak Breakdown of academic impact, for papers by Bin Zhao Breakdown of academic impact, for papers by Ana Cenarro Breakdown of academic impact, for papers by Constantinos C. Tellis Breakdown of academic impact, for papers by Joan-Carles Vallvé Breakdown of academic impact, for papers by Melba Hernandez